▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

ProKidney (NASDAQ: PROK)

$3.06

(8.5%)

$0.24

Price as of August 4, 2025, 12:50 p.m. ET

ProKidney Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
PROK	+29.36%			-72%
S&P	+14.53%	+90.70%	+13.76%	+45%

ProKidney Company Info

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.

News & Analysis

Featured Article

Meet the Biotech Stock That Rocketed 775% Higher

Cory Renauer | Jul 22, 2025

Featured Article

This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?

David Jagielski | Jul 17, 2025

Why Shares of ProKidney Were Dropping Thursday

James Halley | Oct 12, 2023

Two factors led to the stock's slide on Thursday.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services